Karyopharm Therapeutics financials
$1.21−25.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.4M | $35.1M | $34.1M | $44.0M | $37.9M | $30.0M | $30.5M | $38.8M | $42.8M | $33.1M | $33.7M | $36.0M |
| Gross profit | $32.3M | $33.7M | $32.6M | $41.9M | $36.9M | $28.7M | $29.2M | $37.5M | $41.3M | $31.2M | $32.3M | $35.1M |
| Gross margin | 96.8% | 96.2% | 95.6% | 95.2% | 97.2% | 95.7% | 95.6% | 96.6% | 96.6% | 94.2% | 95.6% | 97.5% |
| Operating income | -$22.5M | -$26.8M | -$17.8M | -$15.2M | -$24.4M | -$33.3M | -$31.3M | -$26.3M | -$28.1M | -$33.8M | -$37.8M | -$31.3M |
| Net income | -$67.0M | -$22.4M | -$102.2M | -$33.1M | -$37.3M | -$23.5M | -$30.8M | -$32.1M | $18.3M | -$37.4M | -$41.8M | -$34.5M |
| Net margin | −200.5% | −63.9% | −299.9% | −75.2% | −98.2% | −78.2% | −100.8% | −82.7% | 42.7% | −112.8% | −124.0% | −95.8% |
| Diluted EPS | $-2.32 | $-1.24 | $-5.68 | $-3.82 | $-4.32 | $-2.77 | $-4.11 | $-3.85 | $-2.97 | $-4.85 | $-5.47 | $-4.50 |
| EBITDA | -$22.5M | -$26.7M | -$17.8M | -$15.1M | -$24.3M | -$33.2M | -$31.2M | -$26.2M | -$28.0M | -$33.7M | -$37.7M | -$31.2M |
| Operating cash flow | -$24.9M | -$22.7M | -$11.8M | -$5.9M | -$18.7M | -$39.0M | -$25.8M | -$19.5M | -$38.5M | -$43.7M | -$18.6M | -$29.5M |
| Free cash flow | -$24.9M | -$22.7M | -$11.8M | -$5.9M | -$18.7M | -$39.0M | -$25.9M | -$19.5M | -$38.5M | -$43.9M | -$18.6M | -$29.5M |
| Diluted shares | 28.9M | 24.7M | 18.0M | 8.7M | 8.6M | 8.5M | 7.5M | 8.3M | 10.3M | 7.7M | 7.7M | 7.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $55.0M | $90.8M | $60.5M | $37.7M | $38.7M | $38.8M |
| Short-term investments | $10.1M | $0.00 | $3.2M | $8.2M | $13.0M | $31.2M |
| Total debt | $249.9M | $224.4M | $226.9M | $189.5M | $183.0M | $179.3M |
| Total assets | $111.3M | $131.4M | $108.4M | $96.2M | $104.9M | $127.7M |
| Total liabilities | $441.5M | $397.1M | $401.3M | $365.5M | $343.8M | $333.6M |
| Shareholders' equity | -$330.2M | -$265.6M | -$292.9M | -$269.3M | -$238.9M | -$205.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology